These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 9646008)

  • 1. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of vasodilators. Part II.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jul; 35(1):9-36. PubMed ID: 9673832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists.
    Zannad F; Matzinger A; Larché J
    Am J Hypertens; 1996 Jul; 9(7):633-43. PubMed ID: 8806975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk-benefit assessment of losartan potassium in the treatment of hypertension.
    Burrell LM
    Drug Saf; 1997 Jan; 16(1):56-65. PubMed ID: 9010643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and trends in the drug treatment of essential hypertension.
    van Zwieten PA
    J Hypertens Suppl; 1992 Dec; 10(7):S1-12. PubMed ID: 1363322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL; Porter JA
    Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetic and clinical profiles of angiotensin-converting enzyme inhibitors and calcium antagonists in systemic hypertension.
    Frishman WH
    Am J Cardiol; 1992 Apr; 69(10):17C-25C. PubMed ID: 1546635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic drug interactions with ACE inhibitors.
    Shionoiri H
    Clin Pharmacokinet; 1993 Jul; 25(1):20-58. PubMed ID: 8354016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasodilatory edema: a common side effect of antihypertensive therapy.
    Messerli FH
    Curr Cardiol Rep; 2002 Nov; 4(6):479-82. PubMed ID: 12379167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.